drugset / Trial / NCT06040424

Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT06040424

Phase 3 Unknown 74 enrolled Neutec Ar-Ge San ve Tic A.Ş
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to compare the acute bronchodilator effect of pMDI formed Ipratropium / Levosalbutamol 20 mcg / 50 mcg fixed dose combination or pMDI formed Salbutamol 100 mcg Inhaler and Ipratropium 20 mcg Inhalation Aerosol in combination in stable moderate-severe-very severe COPD patients.

Timeline

Start
2023-09-28
Primary completion
2024-06
Completion
2024-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ipratropium Small molecule 20 ug Inhaled
Comparator Levalbuterol Other / unclassified 50 ug Inhaled
Comparator Levalbuterol Other / unclassified 100 ug Inhaled